Methoserpidine

Methoserpidine
Identifiers
PubChem	71798
UNII	8F8C1JQH53 Y
ATC code	C02AA06
Jmol-3D images	Image 1
SMILES CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=C(C=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
Properties
Molecular formula	C33H40N2O9
Molar mass	608.68 g mol−1
Y (verify) (what is: Y/N?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Methoserpidine is an antihypertensive drug related to reserpine.^[1]

References

1. ^ Jones, D. L.; Michael, A. M.; Ommer, J. P. (1961). "Clinical Trial of Methoserpidine in General Practice". British medical journal 2 (5269): 1738–1741. PMC 1970934. PMID 14452236.  edit

v d e Sympatholytic (and closely related) antihypertensives (C02) Sympatholytics (antagonize α-adrenergic vasoconstriction) Central α2 agonist Clonidine • Guanfacine • Methyldopa # Adrenergic release inhibitors Bethanidine • Bretylium • Debrisoquine • Guanadrel • Guanazodine • Guanethidine • Guanoclor • Guanoxan • Guanazodine • Guanoxabenz • Guanoxan Imidazoline receptor agonist Moxonidine • Rilmenidine Ganglion-blocking/nicotinic antagonist Mecamylamine • Pentolinium • Trimethaphan Peripheral Indirect MAOI Pargyline Adrenergic uptake inhibitor Bietaserpine • Deserpidine • Methoserpidine • Rescinnamine • Reserpine Tyrosine hydroxylase inhibitor Metirosine Direct α1 blockers Prazosin • Indoramin • Trimazosin • Doxazosin • Urapidil Non-selective α blocker Phentolamine Other antagonists Serotonin antagonist Ketanserin Endothelin antagonist (for PH) dual (Bosentan) • selective (Ambrisentan, Sitaxentan) #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III M: VAS anat(a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot noco/syva/cong/lyvd/tumr, sysi/epon, injr proc, drug(C2s+n/3/4/5/7/8/9)

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. v d e

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)